Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
September 2021
-
Pulse UpdateSep 28, 2021FDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC)
-
Pulse UpdateSep 03, 2021Novartis announces discontinuation of CIRRUS-1 study of CFZ533 (iscalimab) in kidney transplant patients
-
Pulse UpdateSep 02, 2021Novartis receives FDA fast track designation for LNA043 in osteoarthritis of the knee